


# 51<sup>st</sup> General Assembly of ERIC Members


ELN Symposium – Tuesday 15<sup>th</sup> March, 2021

# ERIC Membership

- **1742 Members**
- **Distributed amongst 87 countries / >720 different institutions**



# ERIC Membership



# TP53 and IGHV Certification



**226**  
Certified  
Centres from  
39 countries




**11**  
Reference  
Centres



**3**  
Certifying  
Centers



**12**  
Certification Rounds  
completed



Besides Europe, ERIC also has certified centres in Australia, Brazil, Canada, China, India, Palestine and Qatar



**135**  
Certified  
Centres from  
34 countries



**7**  
Reference  
Centres



**2**  
Certifying  
Centers



**7**  
Certification Rounds  
completed



Besides Europe, ERIC also has certified centres in Argentina, Australia, Canada, South Africa, Taiwan, and USA

# Recent ERIC Publications

- **Six-month Antibody Persistence After Bnt162b2 Mrna Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukemia.** Yair Herishanu; Irit Avivi; Shai Levi; Gabi Shefer; Yotam Bronstein; Miguel Morales Moshiashvili; Tomer Ziv; Lydia Scarfò; Chava Perry; Paolo Ghia. **Blood Adv.** 2022 Jan 11;6(1):148-151.
- **COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.** Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A, Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghumyan G, Shrestha A, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik-Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Stamatopoulos K, Ghia P. **Leukemia.** 2021 Dec;35(12):3444-3454
- **Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.** Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales Moshiashvili M, Ziv-Baran T, Shorer Y, Scarfo L, Joffe E, Perry C, Ghia P. **Blood.** 2021 Apr 16:blood.2021011568
- **COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.** Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrengea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P. **Leukemia.** 2020 Sep;34(9):2354-2363.

# Recent ERIC Publications

- Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. *Sutton LA, Ljungström V, Enjuanes A, Cortese D, Skaftason A, Tausch E, Stano Kozubik K, Nadeu F, Armand M, Malcikova J, Pandzic T, Forster J, Davis Z, Oscier D, Rossi D, Ghia P, Strefford JC, Pospisilova S, Stilgenbauer S, Davi F, Campo E, Stamatopoulos K, Rosenquist R, On Behalf Of The European Research Initiative On CLL ERIC. Haematologica. 2021 Mar 1;106(3):682-691.*
- Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece. *Karamanidou C, Xochelli A, Papaioannou M, Moysiadis T, Scarfo L, Mattsson M, Stavroyianni N, Rosenquist R, Ghia P, Stamatopoulos K. Hemasphere. 2021 Feb 23;5(3):e546.*
- EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia. *Eichhorst B, Ghia P. Hemasphere. 2020 Dec 29;5(1):e520.*
- Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. *Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P; GIMEMA, European Research Initiative (ERIC) on CLL, US study group. Cancer Med. 2020 Nov;9(22):8468-8479.*
- Challenges and Solutions for Collecting and Analyzing Real World Data: The Eric CLL Database as an Illustrative Example. *Chatzidimitriou A, Minga E, Chatzikonstantinou T, Moreno C, Stamatopoulos K, Ghia P. Hemasphere. 2020 Sep 30;4(5):e425.*

# ERIC Workshops

**2020**

## ERIC WORKSHOP AT THE EHA-ISHBT HEMATOLOGY TUTORIAL 2020

- 27 FEBRUARY, 2020 (CHANDIGARH, INDIA)

## IG WORKSHOP BY ERIC & THE TURKISH SOCIETY OF HEMATOLOGY

- 24-25 OCTOBER, 2020 (VIRTUAL)

## ERIC INTERNATIONAL MEETING

- 01-03 OCTOBER, 2020 (VIRTUAL)

## ERIC MRD WORKSHOP TAIWAN

- 7-8 NOVEMBER, 2020 (TAIWAN, VIRTUAL)

## SEMINAR SERIES: BIOMARKERS FOR DECISION-MAKING IN CLL

- SEPTEMBER, 2020 (VIRTUAL)

## DIAGNOSTIC SUMMIT: OPTIMISING THE PRECISION MANAGEMENT OF PATIENTS WITH CANCER

- OCTOBER, 2020 (VIRTUAL)

**2021**

## 50<sup>TH</sup> GENERAL ASSEMBLY

- 9 JUNE, 2021 (EHA, VIRTUAL)

## ERIC WORKSHOPS ON MOLECULAR BIOMARKERS IN CLL (VIRTUAL)

- 29-30 SEPTEMBER – 1 OCTOBER, 2021 (MEDITERRANEAN/GULF REGION)
- 12-14 OCTOBER, 2021 (BALTICS/SCANDINAVIA)
- 9-11 NOVEMBER, 2021 (CENTRAL EASTERN EUROPE)
- 23-25 NOVEMBER, 2021 (WESTERN EUROPE)

## ERIC MRD WORKSHOP JAPAN

- 6-7 NOVEMBER, 2021 (JAPAN, VIRTUAL)

## CWCLL/ERIC WORKSHOP ON GENETIC ANALYSIS IN CLL JAPAN

- 10 DECEMBER, 2021 (CHINA, VIRTUAL)

# GenQA and UK NEQAS

ERIC will continue to work with laboratories to achieve accuracy of testing through their initial certification process whilst GenQA and UK NEQAS LI will assure the maintenance of competency among previously certified labs by providing an external quality assessment scheme (EQA). Both the certification and the EQA procedures will follow the same assessment process adhering to ERIC recommendations for analysis and interpretation of TP53 and IG testing.

## Laboratories applying for the initial certification

- To register for ERIC certification go to [www.ericll.org/diagnostics](http://www.ericll.org/diagnostics)
- For further information [office@ericll.org](mailto:office@ericll.org)



## Re-certification for Certified laboratories

- For further information contact [info@genga.org](mailto:info@genga.org) or [office@ericll.org](mailto:office@ericll.org)



# MRD Network

---

The ERIC is launching a project, coordinated by Andy Rawstron (Leeds, UK), to develop [consensus data analysis approaches for MRD analysis in CLL](#) across different software platforms.

- [FORUM on MRD in CLL](#)

**September 7<sup>th</sup>, 2021 at the ELN Symposium in Mannheim (Germany) – IN PERSON**

*ERIC sought for open and thorough discussion on the key aspects of MRD assessment in CLL that could be included in a possible update of the ERIC recommendations. Focus will be, but not exclusively, on core marker panel, time-points, reporting criteria.*

The ERIC is planning to launch a flow-based [MRD certification program](#) for assessment of quality and reliability of the analysis

# ERIC International Meeting 2022



**New frontiers in CLL Research**

Barcelona, 6-8 October 2022

[ericll2022.org](http://ericll2022.org)

**ERIC**

european research initiative on CLL

**SAVE THE DATE**

**SAVE THE DATE**

- For registration: [www.ericll2022.org](http://www.ericll2022.org)